Format

Send to

Choose Destination
Emerg Infect Dis. 2017 May;23(5):809-812. doi: 10.3201/eid2305.161745.

Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium.

Abstract

Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6%) and gyrA (5%). ParC S83 changes were associated with moxifloxacin failure. Combined macrolide/fluoroquinolone-resistance mutations were in 8.6% of specimens, for which recommended therapies would be ineffective.

KEYWORDS:

Australia; GyrA; Mycoplasma genitalium; ParC; antibiotic resistance; antimicrobial resistance; bacteria; moxifloxacin

PMID:
28418319
PMCID:
PMC5403035
DOI:
10.3201/eid2305.161745
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for CDC-NCEZID Icon for PubMed Central
Loading ...
Support Center